As of the end of 2024, more than 700 million doses of HPV vaccine have been distributed since licensure in 2006. Go to footnote 1, Go to footnote 2 Post-licensure surveillance has detected no serious safety issues to date except rare reports of anaphylaxis. The risk of anaphylaxis has been characterized as approximately 1.7 cases per million doses. Go to footnote 3 A systematic review of studies on the safety of HPV vaccines found little-to-no difference among recipients of bivalent, quadrivalent and nonavalent HPV vaccines with regard to serious adverse events. Go to footnote 4, Go to footnote 5
- Go back to footnote reference 1
World Health Organization (no date). Global Advisory Committee on Vaccine Safety: human papillomavirus vaccines. Geneva: World Health Organization (https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines, accessed 23 June 2025).
- Go back to footnote reference 2
World Health Organization (2024). Global vaccine market report 2024. Geneva: World Health Organization (https://www.who.int/publications/m/item/global-vaccine-market-report-2024, accessed 23 June 2025).
- Go back to footnote reference 3
World Health Organization (2017). HPV vaccine: rates of adverse events following immunization. Geneva: World Health Organization (https://www.who.int/publications/m/item/hpv-vaccine-rates-information-sheet , accessed June 24, 2025)
- Go back to footnote reference 4
Human papillomavirus vaccines: Safety topic page [website]. Geneva: World Health Organization; 2022 (https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety, accessed 19 June 2025).
- Go back to footnote reference 5
Demicheli V, Jefferson T, Ferroni E, Rivetti A (2022). Vaccines for preventing human papillomavirus infection in females. Cochrane Database Syst Rev. 2022(5):CD015363. https://doi.org/10.1002/14651858.CD015363.pub2.
